Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens
Joaquín Burgos, Jorge Palacio, Adrián Curran(Lexington City Schools), Lucía Rodríguez‐Vázquez, Berta Raventós(Universitat Autònoma de Barcelona), Sergio Moreno‐Fornés(Generalitat de Catalunya), Maribel Tamayo, Bibiana Morell, Javier Murillas, Josep M. Miró(Hospital Clínic de Barcelona), José Vicente Fernández-Montero, Josep M. Llibre(Badalona Serveis Assistencials), María Pilar Rivero Gracia(Universidad Cardenal Herrera CEU), Toni Vanrell, Hernando Knobel(Hospital General de Granollers), Juan Tiraboschi(Bellvitge University Hospital), Francisco Fanjul(Hospital Universitario Son Espases), Boris Revollo(Institut Català d'Oncologia), Amat-Joaquim Orti, Arkaitz Imaz(Bellvitge University Hospital), Ángeles Jaén, Josep Mallolas(Hospital Clínic de Barcelona), Lluís Force(University Hospital Mútua de Terrassa), Josep Vilà(Hospital Universitari de Vic), Vicenç Falcó(Universitat Autònoma de Barcelona), Amat Orti(Hospital Universitari de Tortosa Verge de la Cinta), José Carlos(Universidad del Desarrollo del Estado de Puebla), Eva López González, Leire Berrocal, Francisco Homar, Juliana Reyes‐Urueña(Generalitat de Catalunya), Freya Gargoulas, Raquel Martín-Iguacel(Odense University Hospital), Andreu Bruguera(Badalona Serveis Assistencials), David Dalmau(University Hospital Mútua de Terrassa), Elisa de Lazzari(Hospital Clínic de Barcelona), Marina Martínez, Jordi Casabona(Generalitat de Catalunya), Joaquim Peraire(Instituto de Salud Carlos III), María del Mar Gutiérrez(Evidence (Italy)), Elena León, Esteve Muntada, Ingrid Vilaró(Hospital Universitari de Vic), Miquel Hortos(Hospital Universitari de Tortosa Verge de la Cinta)
Cited by 22
Related Papers
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006|137